Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Has Average Target Price of $27.14

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have received an average rating of “Buy” from the eleven research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $27.14.

A number of research firms have recently commented on ZVRA. UBS Group reaffirmed a “buy” rating on shares of Zevra Therapeutics in a research note on Thursday, August 20th. Canaccord Genuity Group lowered their target price on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a report on Monday, July 27th. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Guggenheim cut their price target on shares of Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Finally, Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a report on Thursday, August 6th.

Insider Activity at Zevra Therapeutics

In related news, Director Corey Watton sold 12,300 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $11.25, for a total value of $138,375.00. Following the transaction, the director directly owned 1,800 shares of the company’s stock, valued at approximately $20,250. This trade represents a 87.23% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 3.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC purchased a new position in shares of Zevra Therapeutics in the 2nd quarter worth about $28,000. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new position in shares of Zevra Therapeutics in the 4th quarter valued at about $53,000. Tidal Investments LLC purchased a new stake in shares of Zevra Therapeutics during the 2nd quarter worth about $150,000. DGS Capital Management LLC purchased a new stake in shares of Zevra Therapeutics during the 4th quarter worth about $133,000. Finally, WINTON GROUP Ltd increased its position in Zevra Therapeutics by 49.0% during the 2nd quarter. WINTON GROUP Ltd now owns 24,335 shares of the company’s stock worth $349,000 after purchasing an additional 8,001 shares in the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Stock Up 3.5%

Shares of NASDAQ:ZVRA opened at $11.39 on Thursday. The company has a market cap of $676.34 million, a P/E ratio of 12.38 and a beta of 0.98. Zevra Therapeutics has a 52 week low of $8.01 and a 52 week high of $15.03. The business has a fifty day simple moving average of $11.52 and a 200-day simple moving average of $11.37.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.11 by $0.14. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. The firm had revenue of $39.66 million during the quarter, compared to analyst estimates of $33.88 million. Sell-side analysts expect that Zevra Therapeutics will post 0.72 earnings per share for the current fiscal year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.

Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat.